中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Volume 35 Issue 8
Aug.  2019
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2019  >  35(8): 1693-1701

The expert consensus on clinical cure (functional cure) of chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2019.08.008
  • Published Date: 2019-08-20
    Abstract

  • Chronic hepatitis B virus (HBV) infection remains a major world public health problem. Current guidelines for the prevention and treatment of chronic hepatitis B (CHB) have suggested clinical cure (also known as functional cure) as the ideal therapeutic goal, which is associated with decreased risk of cirrhosis and hepatocellular carcinoma. Clinical cure is defined as sustained, undetectable serum HBsAg, HBeAg and HBV DNA with or without seroconversion to anti-HBs, but with the persistence of residual cccDNA, accompanied by resolution of liver injury after the completion of a finite course of treatment. Accumulating data from a series of randomized controlled trials as well as clinical practice have confirmed certain clinical benefit of optimal sequential/combination strategies of direct acting antiviral drugs (DAA) [such as nucleoside analogues (NA) ]or immunomodulators [such as pegylated interferon alpha (PEG-IFN) ]for appropriately selected CHB patients. This consensus provides an updated and comprehensive analysis of the data supporting the use of combination therapies and summarizes the roadmap towards clinical cure of CHB to guide decision-making in clinical practice.

     

    • FullText(HTML)
    • References(99)
  • [1] SCHWEITZER A, HORN J, MIKOLAJCZYK RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection:A systematic review of data published between 1965 and2013[J]. Lancet, 2015, 386 (10003) :1546-1555.
    [2] World Health Organization. Global hepatitis report 2017[R].Licence:CC BY-NC-SA 3. 0 IGO. 2017.
    [3] SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B:A 2015update[J]. Hepatol Int, 2016, 10 (1) :1-98.
    [4] TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67 (4) :1560-1599.
    [5] European Association for the Study of the Liver. EASL 2017clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67 (2) :370-398.
    [6] HOU J, WANG G, WANG F, et al. Guideline of prevention and treatment for chronic hepatitis B (2015 Update) [J]. J Clin Transl Hepatol, 2017, 5 (4) :297-318.
    [7] YUEN MF, WONG DK, FUNG J, et al. HBsAg seroclearance in chronic hepatitis B in Asian patients:Replicative level and risk of hepatocellular carcinoma[J]. Gastroenterology, 2008, 135 (4) :1192-1199.
    [8] NING Q, WU D, WANG G, et al. Roadmap to functional cure of chronic hepatitis B:An expert consensus[J]. J Viral Hepat, 2019.[Epub ahead of print]
    [9] TU T, BUDZINSKA MA, SHACKEL NA, et al. HBV DNA Integration:Molecular mechanisms and clinical implications[J].Viruses, 2017, 9 (4) :e75.
    [10] VISVANATHAN K, SKINNER NA, THOMPSON AJ, et al. Regulation of toll-like receptor-2 expression in chronic hepatitis B by the precore protein[J]. Hepatology, 2007, 45 (1) :102-110.
    [11] OP DEN BROUW ML, BINDA RS, van ROOSMALEN MH, et al. Hepatitis B virus surface antigen impairs myeloid dendritic cell function:A possible immune escape mechanism of hepatitis B virus[J]. Immunology, 2009, 126 (2) :280-289.
    [12] LANG T, LO C, SKINNER N, et al. The hepatitis B e antigen (HBe Ag) targets and suppresses activation of the toll-like receptor signaling pathway[J]. J Hepatol, 2011, 55 (4) :762-769.
    [13] DAS A, HOARE M, DAVIES N, et al. Functional skewing of the global CD8 T cell population in chronic hepatitis B virus infection[J]. J Exp Med, 2008, 205 (9) :2111-2124.
    [14] BONI C, FISICARO P, VALDATTA C, et al. Characterization of hepatitis B virus (HBV) -specific T-cell dysfunction in chronic HBV infection[J]. J Virol, 2007, 81 (8) :4215-4225.
    [15] BERTOLETTI A, KENNEDY P. HBV antiviral immunity:Not all CD8 T cells are born equal[J]. Gut, 2019, 68 (5) :770-773.
    [16] SALIMZADEH L, LE BERT N, DUTERTRE CA, et al. PD-1blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection[J]. J Clin Invest, 2018, 128 (10) :4573-4587.
    [17] TANG L, COVERT E, WILSON E, et al. Chronic hepatitis B infection:A review[J]. JAMA, 2018, 319 (17) :1802-1813.
    [18] LEVRERO M, SUBIC M, VILLERET F, et al. Perspectives and limitations for nucleo (t) side analogs in future HBV therapies[J]. Curr Opin Virol, 2018, 30:80-89.
    [19] DOLMAN GE, KOFFAS A, MASON WS, et al. Why, who and when to start treatment for chronic hepatitis B infection[J].Curr Opin Virol, 2018, 30:39-47.
    [20] LIU F, WANG XW, CHEN L, et al. Systematic review with meta-analysis:Development of hepatocellular carcinoma in chronic hepatitis B patients with hepatitis B surface antigen seroclearance[J]. Aliment Pharmacol Ther, 2016, 43 (12) :1253-1261.
    [21] KONG Y, YOU H, JIA J. Oral antiviral therapy reduces the risk of hepatocellular carcinoma in persons with chronic hepatitis B infection:Combining evidence and common sense[J]. Hepatol Int, 2016, 10 (2) :239-241.
    [22] LEVRERO M, POLLICINO T, PETERSEN J, et al. Control of cccDNA function in hepatitis B virus infection[J]. J Hepatol, 2009, 51 (3) :581-592.
    [23] SUNG JJ, WONG ML, BOWDEN S, et al. Intrahepatic hepatitis B virus covalently closed circular DNA can be a predictor of sustained response to therapy[J]. Gastroenterology, 2005, 128 (7) :1890-1897.
    [24] WERLE-LAPOSTOLLE B, BOWDEN S, LOCARNINI S, et al.Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy[J].Gastroenterology, 2004, 126 (7) :1750-1758.
    [25] LAI CL, WONG D, IP P, et al. Reduction of covalently closed circular DNA with long-term nucleos (t) ide analogue treatment in chronic hepatitis B[J]. J Hepatol, 2017, 66 (2) :275-281.
    [26] SADLER AJ, WILLIAMS BR. Interferon-inducible antiviral effectors[J]. Nat Rev Immunol, 2008, 8 (7) :559-568.
    [27] WIELAND SF, EUSTAQUIO A, WHITTEN-BAUER C, et al.Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids[J]. Proc Natl Acad Sci U S A, 2005, 102 (28) :9913-9917.
    [28] BELLONI L, ALLWEISS L, GUERRIERI F, et al. IFN-αinhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome[J]. J Clin Invest, 2012, 122 (2) :529-537.
    [29] BUSTER EH, HANSEN BE, LAU GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa[J]. Gastroenterology, 2009, 137 (6) :2002-2009.
    [30] YANG HC, KAO JH. Viral hepatitis. HBV cure—can we pin our hopes on immunotherapy?[J]. Nat Rev Gastroenterol Hepatol, 2015, 12 (3) :129-131.
    [31] WU D, NING Q. Toward a cure for hepatitis B virus infection:Combination therapy involving viral suppression and immune modulation and long-term outcome[J]. J Infect Dis, 2017, 216 (Suppl 8) :s771-s777.
    [32] TESTONI B, LEVRERO M, ZOULIM F. Challenges to a cure for HBV infection[J]. Semin Liver Dis, 2017, 37 (3) :231-242.
    [33] NASSAL M. HBV cccDNA:Viral persistence reservoir and key obstacle for a cure of chronic hepatitis B[J]. Gut, 2015, 64 (12) :1972-1984.
    [34] THIMME R, DANDRI M. Dissecting the divergent effects of interferon-alpha on immune cells:Time to rethink combination therapy in chronic hepatitis B[J]. J Hepatol, 2013, 58 (2) :205-209.
    [35] MICCO L, PEPPA D, LOGGI E, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B[J]. J Hepatol, 2013, 58 (2) :225-233.
    [36] PENNA A, LACCABUE D, LIBRI I, et al. Peginterferon-αdoes not improve early peripheral blood HBV-specific T-cell responses in HBe Ag-negative chronic hepatitis[J]. J Hepatol, 2012, 56 (6) :1239-1246.
    [37] CHEN T, ZHU L, SHI A, et al. Functional restoration of CD56bright NK cells facilitates immune control via IL-15 and NKG2D in patients under antiviral treatment for chronic hepatitis B[J]. Hepatol Int, 2017, 11 (5) :419-428.
    [38] BONI C, LACCABUE D, LAMPERTICO P, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos (t) ide analogues[J]. Gastroenterology, 2012, 143 (4) :963-973. e9.
    [39] GILL US, KENNEDY P. The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B:Considerations for future novel therapeutics[J]. J Viral Hepat, 2019, 26 (1) :4-15.
    [40] TAN AT, HOANG LT, CHIN D, et al. Reduction of HBV replication prolongs the early immunological response to IFNαtherapy[J]. J Hepatol, 2014, 60 (1) :54-61.
    [41] de NIET A, STELMA F, JANSEN L, et al. Restoration of T cell function in chronic hepatitis B patients upon treatment with interferon based combination therapy[J]. J Hepatol, 2016, 64 (3) :539-546.
    [42] YAN W, WU D, WANG X, et al. Upregulation of NKG2C+natural killer cells, TLR-2 expression on monocytes and downregulation of regulatory T-cells influence PEG-IFN treatment efficacy in entecavir-suppressed patients with CHB[J]. Antivir Ther, 2015, 20 (6) :591-602.
    [43] HAN M, LI Y, WU W, et al. Altered expression of interferonstimulated genes is strongly associated with therapeutic outcomes in hepatitis B virus infection[J]. Antiviral Res, 2017, 147:75-85.
    [44] SHI A, ZHANG X, XIAO F, et al. CD56brightnatural killer cells induce HBsAg reduction via cytolysis and cccDNA decay in long-term entecavir-treated patients switching to peginterferon alfa-2a[J]. J Viral Hepat, 2018, 25 (11) :1352-1362.
    [45] LAU GK, PIRATVISUTH T, LUO KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBe Ag-positive chronic hepatitis B[J]. N Engl J Med, 2005, 352 (26) :2682-2695.
    [46] MARCELLIN P, LAU GK, BONINO F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBe Ag-negative chronic hepatitis B[J]. N Engl J Med, 2004, 351 (12) :1206-1217.
    [47] PICCOLO P, LENCI I, DEMELIA L, et al. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B[J]. Antivir Ther, 2009, 14 (8) :1165-1174.
    [48] MARCELLIN P, WURSTHORN K, WEDEMEYER H, et al. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy[J]. J Hepatol, 2015, 62 (1) :41-47.
    [49] TANGKIJVANICH P, CHITTMITTRAPRAP S, POOVORAWAN K, et al. A randomized clinical trial of peginterferon alpha-2b with or without entecavir in patients with HBe Ag-negative chronic hepatitis B:Role of host and viral factors associated with treatment response[J]. J Viral Hepat, 2016, 23 (6) :427-438.
    [50] MARCELLIN P, AHN SH, MA X, et al. Combination of tenofovir disoproxil fumarate and peginterferonα-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B[J]. Gastroenterology, 2016, 150 (1) :134-144. e10.
    [51] AHN SH, MARCELLIN P, MA X, et al. Hepatitis B surface antigen loss with tenofovir disoproxil fumarate plus peginterferon alfa-2a:Week 120 analysis[J]. Dig Dis Sci, 2018, 63 (12) :3487-3497.
    [52] HAGIWARA S, NISHIDA N, WATANABE T, et al. Sustained antiviral effects and clearance of hepatitis surface antigen after combination therapy with entecavir and pegylated interferon in chronic hepatitis B[J]. Antivir Ther, 2018, 23 (6) :513-521.
    [53] SERFATY L, THABUT D, ZOULIM F, et al. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone:Results of a pilot study[J]. Hepatology, 2001, 34 (3) :573-577.
    [54] NING Q, HAN M, SUN Y, et al. Switching from entecavir to PegIFN alfa-2a in patients with HBe Ag-positive chronic hepatitis B:A randomised open-label trial (OSST trial) [J]. J Hepatol, 2014, 61 (4) :777-784.
    [55] HAN M, JIANG J, HOU J, et al. Sustained immune control in HBe Ag-positive patients who switched from entecavir therapy to pegylated interferon-α2a:1 year follow-up of the OSST study[J]. Antivir Ther, 2016, 21 (4) :337-344.
    [56] BOGLIONE L, D'AVOLIO A, CARITI G, et al. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes[J]. J Viral Hepat, 2013, 20 (4) :e11-e19.
    [57] TAMAKI N, KUROSAKI M, KUSAKABE A, et al. Hepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon[J]. J Viral Hepat, 2017, 24 (8) :672-678.
    [58] XIE Q, ZHOU H, BAI X, et al. A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B"e"antigenpositive chronic hepatitis B[J]. Clin Infect Dis, 2014, 59 (12) :1714-1723.
    [59] HU P, SHANG J, ZHANG W, et al. HBsAg loss with Peg-interferon alfa-2a in hepatitis B patients with partial response to nucleos (t) ide analog:New switch study[J]. J Clin Transl Hepatol, 2018, 6 (1) :25-34.
    [60] CHAN H, CHAN F, HUI AJ, et al. Switching to peginterferon for chronic hepatitis B patients with hepatitis B e antigen seroconversion on entecavir-A prospective study[J]. J Viral Hepat, 2019, 26 (1) :126-135.
    [61] WU D, WANG P, HAN M, et al. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients:The Endeavor study[J]. Hepatol Int, 2019.
    [62] KITTNER JM, SPRINZL MF, GRAMBIHLER A, et al. Adding pegylated interferon to a current nucleos (t) ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B[J]. J Clin Virol, 2012, 54 (1) :93-95.
    [63] OUZAN D, PNARANDA G, JOLY H, et al. Add-on peg-interferon leads to loss of HBs Ag in patients with HBe Ag-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs[J]. J Clin Virol, 2013, 58 (4) :713-717.
    [64] CHI H, HANSEN BE, GUO S, et al. Pegylated interferon alfa-2b add-on treatment in hepatitis B virus envelope antigen-positive chronic hepatitis B patients treated with nucleos (t) ide analogue:A randomized, controlled trial (PEGON) [J]. J Infect Dis, 2017, 215 (7) :1085-1093.
    [65] LI GJ, YU YQ, CHEN SL, et al. Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBe Ag) seroconversion in HBe Ag-positive chronic hepatitis B patients receiving longterm entecavir treatment[J]. Antimicrob Agents Chemother, 2015, 59 (7) :4121-4128.
    [66] DEGASPERI E, GALMOZZI E, FACCHETTI F, et al. TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals[J].J Viral Hepat, 2019.[Epub ahead of print]
    [67] BOURLIRE M, RABIEGA P, GANNE-CARRIE N, et al.Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos (t) ide analogue therapy versus nucleos (t) ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA:A randomised, controlled, open-label trial[J]. Lancet Gastroenterol Hepatol, 2017, 2 (3) :177-188.
    [68] BROUWER WP, XIE Q, SONNEVELD MJ, et al. Adding pegylated interferon to entecavir for hepatitis B e antigen-positive chronic hepatitis B:A multicenter randomized trial (ARES study) [J]. Hepatology, 2015, 61 (5) :1512-1522.
    [69] JINDAL A, VYAS AK, KUMAR D, et al. Higher efficacy of pegylated interferon-α2b add-on therapy in hepatitis B envelope antigen-positive chronic hepatitis B patients on tenofovir monotherapy[J]. Hepatol Res, 2018, 48 (6) :451-458.
    [70] CANNIZZO ES, TINCATI C, BINDA F, et al. Unconventional T cells in chronic hepatitis B patients on long-term suppressive therapy with tenofovir followed by a Peg-IFN add-on strategy:A randomized study[J]. J Viral Hepat, 2018, 25 (4) :381-390.
    [71] QIU K, LIU B, LI SY, et al. Systematic review with meta-analysis:Combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance[J]. Aliment Pharmacol Ther, 2018, 47 (10) :1340-1348.
    [72] YAN L, ZHU C, LI J, et al. Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients[J]. Infect Drug Resist, 2018, 11:2001-2009.
    [73] TATSUKAWA Y, TSUGE M, KAWAKAMI Y, et al. Reduction of hepatitis B surface antigen in sequential versus add-on pegylated interferon to nucleoside/nucleotide analogue therapy in HBe-antigen-negative chronic hepatitis B patients:A pilot study[J]. Antivir Ther, 2018, 23 (8) :639-646.
    [74] LIM SG. HCV management in resource-constrained countries[J]. Hepatol Int, 2017, 11 (3) :245-254.
    [75] HONER ZU SIEDERDISSEN C, CORNBERG M. The role of HBsAg levels in the current management of chronic HBV infection[J]. Ann Gastroenterol, 2014, 27 (2) :105-112.
    [76] MARTINOT-PEIGNOUX M, LAPALUS M, ASSELAH T, et al.HBsAg quantification:Useful for monitoring natural history and treatment outcome[J]. Liver Int, 2014, 34 (Suppl 1) :97-107.
    [77] WU D, HAN M, NING Q. An integration of deep viral suppression with sequential immune modulation (cocktail therapy) to restore antiviral capacity:The future of chronic hepatitis B?[J]. J Hepatol, 2015, 62 (1) :240-241.
    [78] HUANG J, ZHANG K, CHEN W, et al. Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBs Ag levels and HBV DNA suppressed by NAs[J]. Sci Rep, 2017, 7 (1) :13383.
    [79] HAN MF, WU D, TAN DM, et al. Combination/sequential therapy with ETV, Peg-IFN alpha-2b and GMCSF enhanced HBsAg loss and appearance of HBsAb in NA suppressed CHB patients (the Anchor A study) :An interim analysis[J]. Hepatology, 2017:o29.
    [80] GAO Z, ZHU X, LIN B, et al. The optimizing treatment of peg interferon alfa in hbeag negative chronic hepatitis B patients with low level HBsAg:A multicenter real world study (Interferon Cure Study, I CURE Study) [J]. Hepatology, 2018, 68:246A.
    [81] XIE Q, CAI W, OUYANG LJ, et al. Effectiveness of response-guided peginterferon alfa-2a therapy in nucleos (t) ide analogues treated patients with HBe Ag-positive chronic hepatitis B:Interim analysis of a prospective, multicenter, randomized study[J]. Hepatology 2018, 68:232A.
    [82] SU TH, HSU CS, CHEN CL, et al. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B[J]. Antivir Ther, 2010, 15 (8) :1133-1139.
    [83] TSENG TC, KAO JH. Clinical utility of quantitative HBs Ag in natural history and nucleos (t) ide analogue treatment of chronic hepatitis B:New trick of old dog[J]. J Gastroenterol, 2013, 48 (1) :13-21.
    [84] CAO Z, LIU Y, MA L, et al. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha[J]. Hepatology, 2017, 66 (4) :1058-1066.
    [85] SUN J, MA H, XIE Q, et al. Response-guided peginterferon therapy in patients with HBe Ag-positive chronic hepatitis B:A randomized controlled study[J]. J Hepatol, 2016, 65 (4) :674-682.
    [86] WANG CC, TSENG KC, HSIEH TY, et al. Assessing the durability of entecavir-treated hepatitis B using quantitative HBsAg[J]. Am J Gastroenterol, 2016, 111 (9) :1286-1294.
    [87] FUNG J, CHEUNG KS, WONG DK, et al. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B eantigen seroclearance[J]. Hepatology, 2018, 68 (2) :462-472.
    [88] HOU FQ, SONG LW, YUAN Q, et al. Quantitative hepatitis B core antibody level is a new predictor for treatment response in HBe Ag-positive chronic hepatitis B patients receiving peginterferon[J]. Theranostics, 2015, 5 (3) :218-226.
    [89] FAN R, SUN J, YUAN Q, et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBe Ag seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos (t) ide analogues[J]. Gut, 2016, 65 (2) :313-320.
    [90] XU JH, SONG LW, LI N, et al. Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir[J]. J Viral Hepat, 2017, 24 (2) :148-154.
    [91] HSU YC, TSENG CH, KAO JH. Quantification of hepatitis B core antibody helps predict clinical relapse after cessation of nucleos (t) ide analogues in chronic hepatitis B Patients:More needs to be done[J]. Clin Gastroenterol Hepatol, 2019, 17 (5) :1000-1001.
    [92] HU HH, LIU J, CHANG CL, et al. Level of hepatitis B (HB) Core antibody associates with seroclearance of HBV DNA and HB surface antigen in HB e antigen-seronegative patients[J]. Clin Gastroenterol Hepatol, 2019, 17 (1) :172-181. e1.
    [93] TANAKA E, MATSUMOTO A. Guidelines for avoiding risks resulting from discontinuation of nucleoside/nucleotide analogs in patients with chronic hepatitis B[J]. Hepatol Res, 2014, 44 (1) :1-8.
    [94] WANG J, SHEN T, HUANG X, et al. Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound[J]. J Hepatol, 2016, 65 (4) :700-710.
    [95] van BMMEL F, BARTENS A, MYSICKOVA A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors[J]. Hepatology, 2015, 61 (1) :66-76.
    [96] WANG J, CHEN X, WU Y, et al. Serum HBV RNA is a potential predictor of hepatitis B surface antigen reversion[J]. Hepatol Commun, 2018, 2 (10) :1168-1171.
    [97] WU Y, LIU Y, LU J, et al. Durability of Interferon-induced Hepatitis B Surface Antigen Seroclearance[J]. Clin Gastroenterol Hepatol, 2019.[Epub ahead of print]
    [98] YIP TC, WONG GL, CHAN HL, et al. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos (t) ide analogues[J]. J Hepatol, 2019, 70 (3) :361-370.
    [99] KOFFAS A, DOLMAN GE, KENNEDY PT. Hepatitis B virus reactivation in patients treated with immunosuppressive drugs:A practical guide for clinicians[J]. Clin Med (Lond) , 2018, 18 (3) :212-218.
    • Relative Articles
    • Supplements(0)
    • Cited By

  • Cited by

    Periodical cited type(72)

    1. 俞晓琦，张欣欣. 乙型肝炎病毒基因整合对功能性治愈的影响. 临床肝胆病杂志. 2025(01): 24-29 . 本站查看
    2. 高娜，高志良. 慢性乙型肝炎功能性治愈离完全治愈还有多远？. 临床肝胆病杂志. 2025(01): 15-23 . 本站查看
    3. 王怡恺，吴凤萍，刘晨瑞，郝苗，吕莎莎，张苗苗，党双锁，张欣. Mindin蛋白在经聚乙二醇干扰素α-2b治疗的慢性乙型肝炎中的动态变化及意义. 临床肝胆病杂志. 2024(01): 52-57 . 本站查看
    4. 刘义思，任姗，郑素军，陈新月. 乙型肝炎疫苗——从预防到治疗. 临床肝胆病杂志. 2024(05): 1021-1025 . 本站查看
    5. 蔡晓娟，汪美华，毛莉萍，缪幼菡，姚超，朱晓红. 恩替卡韦序贯联合聚乙二醇干扰素α-2b治疗低水平HBsAg阳性CHB患者疗效观察. 中西医结合肝病杂志. 2024(07): 587-591 .
    6. 刘伟伟，史晓玉，王乐，徐琳娟. 恩替卡韦联合前列地尔治疗慢性乙型肝炎并发肝硬化腹水的效果分析. 中国实用医刊. 2024(12): 76-79 .
    7. 朱豫萌，李国涛. HBV感染者HBV-DNA载量与血小板参数、炎性因子的关系探讨. 黑龙江医学. 2024(16): 1923-1925+1928 .
    8. 宫雪莲，王鹏雁，李卫，田昊，张艳，孙英华，陈锡莲. 聚乙二醇干扰素α-2b治疗低HBeAg水平慢性乙型肝炎安全性及疗效预测因素. 国际医药卫生导报. 2024(16): 2771-2776 .
    9. 木唤，许丹青，刘春云，刘立. 低HBsAg水平乙型肝炎患者使用干扰素治疗期间HBsAg与TSH的关系. 重庆医学. 2024(18): 2826-2829 .
    10. 何谱，刘文宗. 抗病毒治疗慢性乙型肝炎患者发生低病毒血症的危险因素. 肝脏. 2024(09): 1105-1108 .
    11. 李思泽，李小科，杜宏波，郑世豪，邹翔云，杨俞铖，叶永安. 慢性乙型肝炎中医证型及证素分布规律研究. 中西医结合肝病杂志. 2024(10): 875-878 .
    12. 刘迪，王赵琛，翟晓梅. HIV治愈研究的伦理思考：价值与挑战. 医学与哲学. 2024(23): 10-15 .
    13. 中国抗癌协会肿瘤临床研究管理学专业委员会，中国医师协会感染科医师分会，中国抗癌协会乳腺肿瘤整合康复专业委员会，中国医师协会外科医师分会乳腺外科专家工作组，国家肿瘤质控中心乳腺癌专家委员会，重庆市医师协会感染科医师分会，重庆市临床医学研究联合会. 乳腺癌患者化疗期间乙型肝炎病毒及丙型肝炎病毒再激活预防管理中国专家共识(2024版). 中华内分泌外科杂志. 2024(06): 751-760 .
    14. 刘璐，孙明瑜. 乙型肝炎病毒相关性肾炎中西医诊疗进展. 中西医结合肝病杂志. 2023(01): 82-85 .
    15. 王春艳，纪冬，陈艳，周光德，董政，王建军，陈国凤，杨永平. 慢性乙型肝炎患者经恩替卡韦治疗后获得显著组织学应答的影响因素及列线图模型构建. 解放军医学杂志. 2023(02): 143-150 .
    16. 任艳，卞丹丹，梁晨，蒋莹莹，王扬，赵景，陈煜，段钟平，陈新月，郑素军. 血清鞘脂联合定量HBsAg对核苷（酸）类似物经治慢性乙型肝炎患者加用聚乙二醇干扰素α后HBsAg阴转的预测价值. 转化医学杂志. 2023(01): 15-21 .
    17. 章申琰，沈忠良，张继明. 乙型肝炎核心相关抗原的分子基础与临床应用. 微生物与感染. 2023(01): 35-45 .
    18. 邓雯，蒋婷婷，毕潇月，杨柳，林妍洁，张璐，李明慧. 干扰素治疗慢性乙型肝炎研究进展. 中国肝脏病杂志(电子版). 2023(02): 1-6 .
    19. 李宽，宁会彬，靳慧鸣，彭真，尚佳. 聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者血清HBsAg清除率的效果分析. 临床肝胆病杂志. 2023(08): 1819-1824 . 本站查看
    20. 胡义亭，赵娜，白万军，邱博，吴茵，宋浩静，张建，董占军. 基于医疗机构的治疗慢性乙型肝炎的核苷（酸）类似物的卫生技术评估. 中国药事. 2023(09): 1033-1046 .
    21. 谭子跃. 干扰素合并恩替卡韦治疗乙型病毒性肝炎患者的疗效及对患者肝功能的影响. 医学信息. 2023(20): 137-140 .
    22. 贺潇瑾，龙云铸，周娟，李丹，周青，袁婷，卿玲，黄莎，陈芝慧，谭英征. 血清乙型肝炎病毒RNA监测聚乙二醇干扰素治疗核苷(酸)类似物经治低病毒载量慢性乙型肝炎患者疗效. 临床军医杂志. 2023(10): 1091-1095 .
    23. 南然，席奇，刘永刚，宋春荣. 恩替卡韦联合复方鳖甲软肝片治疗乙型肝炎肝衰竭的临床效果. 检验医学与临床. 2023(21): 3105-3108+3113 .
    24. 吴宝灵，徐龙，余海滨，徐贞秋，吴敏，张伟，范声春，李艳艳，李金明. 血清HBsAg、HBV RNA水平对慢性乙型肝炎患者核苷(酸)类药物治疗停药预测的价值. 实用临床医学. 2023(05): 1-4 .
    25. 王佳露，席德扬，颜学兵，季芳，李春杨. 聚乙二醇干扰素α-2b治疗HBeAg阴性慢性乙型肝炎患者实现HBsAg清除的预测因素及列线图构建. 临床肝胆病杂志. 2023(12): 2809-2816 . 本站查看
    26. 潘微微，宋琦睿，连江山. 慢性乙型肝炎实现临床治愈的必要性及新方案探索. 临床内科杂志. 2023(12): 807-810 .
    27. 陈芝慧，谭英征，龙云铸. 趋化因子配体13在常见感染性病原体感染中的表达及意义. 新发传染病电子杂志. 2023(05): 80-84 .
    28. 邹磊，王大伟，施翠芬，王磊，王琪，杨国亚，支星，桑达文. 慢性乙型肝炎长期核苷(酸)类似物治疗过程中HBV储存库的变化规律研究. 中国现代药物应用. 2023(24): 82-85 .
    29. 黄慧琴，谷斌，张春梅，侯小兰，宁峰，贺鹏志，李璐，卢恒剑. 核苷(酸)类似物经治CHB患者联合聚乙二醇干扰α-2b治疗的临床研究. 医学信息. 2022(01): 155-157 .
    30. 陈圆圆，陈川铁，陈军. 聚乙二醇干扰素α-2b治疗慢性乙型肝炎导致严重贫血2例. 中国热带医学. 2022(02): 186-190 .
    31. 姚伟. 不同免疫检验方法检测乙型肝炎病毒感染血清学标志物的临床价值研究. 系统医学. 2022(02): 57-60 .
    32. 刘影，徐汉辰，王磊. 中医药对慢性乙型肝炎免疫调节作用概述. 上海中医药杂志. 2022(05): 93-97 .
    33. 王晓红，沈爱春，王丽净. 恩替卡韦联合扶正化瘀胶囊治疗乙肝肝硬化对患者血清纤维化标志物的影响. 当代医学. 2022(14): 95-97 .
    34. 吴凤萍，鲁瑞，刘怡欣，李梅，石娟娟，党双锁. 基于GEO数据库筛选慢性乙型病毒性肝炎患者对干扰素α治疗无应答相关的关键免疫基因和通路. 西安交通大学学报(医学版). 2022(03): 407-412 .
    35. 刘炜炜，马陈斌，田芝奥，顾征太，吴霞. 肝宁片联合替诺福韦酯对甲胎蛋白升高慢性乙型病毒性肝炎患者血清AFP水平、APRI评分及肝纤维化程度的影响. 中西医结合肝病杂志. 2022(06): 516-519 .
    36. 黄燕，张琼月，罗二平，赵卫峰，甘建和. HBsAg>3000 IU/mL慢性乙型肝炎非优势人群临床治愈2例报告. 临床肝胆病杂志. 2022(07): 1608-1611 . 本站查看
    37. 陈诚，杨青青，陈邦涛，陈伟庆. 血清IL-17A通过抑制DEL-1参与慢性乙型肝炎发病的机制研究. 中国免疫学杂志. 2022(12): 1494-1498 .
    38. 孙华宝，李美琦，赖启南，斯志娟，漆童丰，王淑梅. 血清HBV RNA定量检测在慢性乙肝患者抗病毒治疗中临床研究. 实验与检验医学. 2022(03): 306-309 .
    39. 鲁瑞，党双锁，刘怡欣，王怡恺，刘晨瑞，李亚萍，吴凤萍，李梅. 富马酸替诺福韦酯治疗的慢性乙型肝炎患者3年血清HBV DNA和HBsAg的动态变化. 临床肝胆病杂志. 2022(10): 2224-2229 . 本站查看
    40. 程齐齐，杨丽霞，蔡天盼，王亮，孙俊，梁佳圆，刘丽萍，甘厦，阮宁杭，葛善飞. 核苷（酸）类似物初治的慢性乙型肝炎患者发生低病毒血症的影响因素及其动态变化分析. 临床肝胆病杂志. 2022(12): 2716-2722 . 本站查看
    41. 朱雪丽，林照坤，王丽芸. HBV pgRNA表达水平与慢性乙型肝炎患者核（苷）酸类似物治疗反应性的相关性. 实用医学杂志. 2022(20): 2585-2589+2596 .
    42. 钟抒苡，刘寿荣. 抗病毒治疗后HBV准种动态变化及不同感染下的演变过程. 中西医结合肝病杂志. 2022(11): 1053-1056 .
    43. 彭月，周喜汉，于莹莹，柏鸽，黎明吉. 免疫细胞在肝纤维化发生发展及治疗中的作用机制. 山东医药. 2021(04): 101-104 .
    44. 叶永安. 慢性乙型肝炎的治疗现状与中医药“免疫孵育”策略的实践. 中西医结合肝病杂志. 2021(02): 97-101 .
    45. 王浩楠，梁士兵，姚晓玲，来保勇，文天元，苏宁. 复方甘草酸苷注射液改善慢性乙型肝炎肝损伤疗效和安全性的系统评价与Meta分析. 中国中药杂志. 2021(03): 694-702 .
    46. 吴凤萍，李妙羡，王怡恺，鲁瑞，刘怡欣，党双锁. 恩替卡韦单药治疗慢性乙型肝炎患者5年HBsAg与HBV DNA的动态变化. 临床肝胆病杂志. 2021(05): 1047-1052 . 本站查看
    47. 鲁凤民，封波，郑素军，蒋素贞，杨瑞锋，福军亮，纪冬，党双锁，鲁晓擘，陈红松，陈新月，任红，高志良，南月敏，徐小元，俊奇，张文宏，庄辉. 核苷(酸)类似物经治的慢性乙型肝炎患者低病毒血症的研究现状. 临床肝胆病杂志. 2021(06): 1268-1274 . 本站查看
    48. 李广平，张红心，张蕾，周鹏翔，王亚囡. 透明质酸、Ⅳ型胶原、APRI及纤维蛋白原-4对乙型肝炎后肝纤维化的诊断价值. 临床和实验医学杂志. 2021(13): 1385-1388 .
    49. 段金伟，张鹏，张婧，曾婉嘉，鲁凤民. 慢性HBV感染人群血清HBsAg清除的影响因素及其临床意义. 临床肝胆病杂志. 2021(07): 1682-1685 . 本站查看
    50. 朱志强，姜太一，吴昊. 男男性行为者HIV感染队列中新发HBV感染的特点及影响因素. 中国艾滋病性病. 2021(08): 859-861 .
    51. 张瑜，路青华，曹海芳，张生荣. 聚乙二醇干扰素联合恩替卡韦对慢性乙型肝炎患者肝功能及肝纤维化的影响. 医学信息. 2021(17): 114-116 .
    52. 王嘉悦，李天驹，付豪，秦波. 聚乙二醇干扰素治疗慢性乙型病毒性肝炎早期HBsAg快速下降的临床及免疫学特征研究. 中国感染与化疗杂志. 2021(05): 557-565 .
    53. 吴凤萍，鲁瑞，刘怡欣，王怡恺，田燕，张欣，贾晓黎，党双锁. 核苷(酸)类似物序贯联合聚乙二醇干扰素α治疗血清HBsAg低水平的慢性乙型肝炎患者疗效分析. 实用肝脏病杂志. 2021(05): 677-680 .
    54. 蒋丹容. 恩替卡韦分散片治疗慢性乙型肝炎的临床效果及对肝功能的影响. 临床合理用药杂志. 2021(32): 58-60 .
    55. 安子英，丁洋. 慢性乙型肝炎病毒感染的临床治愈策略. 中国实用内科杂志. 2021(11): 941-945 .
    56. 段飞云，陈晓明，胡汝源，陈建萍，杨桂芝，李瑞忠，马婉聪. 2017—2020年大理州健康人群乙型肝炎血清学时空相关性分析. 国际病毒学杂志. 2021(05): 412-415 .
    57. 齐海峰，金峰花，崔玉顺，李香玉. 基于健康管理模式的健康教育对155例慢性乙型肝炎患者生命质量的影响. 延边大学医学学报. 2021(03): 201-203 .
    58. 翁奉武，郭丽颖，李秋伟，李力，赵立聪，孙小雪，尹美君，贾建伟. 外周血淋巴细胞亚群在慢性HBV感染过程中表达的变化分析. 临床肝胆病杂志. 2020(01): 65-69 . 本站查看
    59. 张晨，尚立. 阿德福韦酯联合重组人干扰素α_2b注射液治疗乙型病毒性肝炎患者的疗效. 临床医学研究与实践. 2020(05): 46-48 .
    60. 李璟，杜虹. 唐都医院传染科2013—2019年收治的肝病患者的流行病学分析. 临床医学研究与实践. 2020(10): 1-2+5 .
    61. 刘小菊，张政. 从HBV特异性免疫细胞角度谈慢性乙型肝炎功能性治愈. 临床肝胆病杂志. 2020(05): 977-979 . 本站查看
    62. 王颖，赵奎，秦建忠. HBV cccDNA、HBsAg、HBV pgRNA联合检测对恩替卡韦治疗HBeAg阳性慢性乙型肝炎效果的预测价值. 临床肝胆病杂志. 2020(05): 1008-1013 . 本站查看
    63. 高晓红，成妮，曹姣姣. 聚乙二醇干扰素α-2b治疗乙型肝炎肝硬化实现临床治愈1例报告. 临床肝胆病杂志. 2020(06): 1347-1348 . 本站查看
    64. 蒋莹莹，郑素军. 核苷(酸)类似物治疗慢性乙型肝炎发生HBe Ag血清学转换的预测标志物. 临床肝胆病杂志. 2020(06): 1358-1361 . 本站查看
    65. 闫秀丽，商嘉玮，苏式兵，胡义扬，张辉. 慢性乙型病毒性肝炎肝胆湿热证和肝郁脾虚证患者尿液中microRNAs的表达研究. 上海中医药杂志. 2020(07): 39-46+51 .
    66. 陈华仙，韦嘉. HBeAg阴性慢性乙型肝炎的诊治进展. 临床肝胆病杂志. 2020(07): 1612-1614 . 本站查看
    67. 邱效东，常亚丽，周亚伟，赵珺，桑坦，翟丽亚，陈昀. 伊布替尼致乙肝病毒再激活1例报告并文献复习. 山东医药. 2020(26): 57-60 .
    68. 陈希，崔毅峙，王通. 基于茎环引物探针法定量检测乙型肝炎病毒miR-3的方法学建立. 中国病理生理杂志. 2020(09): 1721-1728 .
    69. 马路园，赵彩彦. 从2019《新指南》谈慢性乙型病毒性肝炎抗病毒治疗进展. 河北医科大学学报. 2020(10): 1117-1120+1125 .
    70. 王欣茹，肖丽，耿爱文，咸建春. 聚乙二醇干扰素治疗慢性乙型肝炎诱发血栓性血小板减少性紫癜1例报告. 临床肝胆病杂志. 2020(11): 2534-2536 . 本站查看
    71. 陈诗琦，毛日成，张继明. 乙型肝炎病毒核心蛋白变构调节剂的研究进展. 微生物与感染. 2020(05): 322-330 .
    72. 王晶晶，纪冬，陈国凤. 慢性乙型肝炎的治愈现状. 传染病信息. 2020(06): 566-570 .

    Other cited types(34)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (2272) PDF downloads(1365) Cited by(106)
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1659]YesterdayPV[2864]TodayIP[26]TodayPV[42]Online[51]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return